JP2016516808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516808A5 JP2016516808A5 JP2016508288A JP2016508288A JP2016516808A5 JP 2016516808 A5 JP2016516808 A5 JP 2016516808A5 JP 2016508288 A JP2016508288 A JP 2016508288A JP 2016508288 A JP2016508288 A JP 2016508288A JP 2016516808 A5 JP2016516808 A5 JP 2016516808A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- bcl
- activity
- amount
- downregulates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 23
- 230000000694 effects Effects 0.000 claims 12
- 102100015655 BCL2L1 Human genes 0.000 claims 8
- 101710032374 BCL2L1 Proteins 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000003902 lesions Effects 0.000 claims 4
- 230000000699 topical Effects 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000009856 Lung Disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000003176 fibrotic Effects 0.000 claims 2
- 230000002757 inflammatory Effects 0.000 claims 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical group C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102000014005 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 claims 1
- 108050003898 Cyclin-dependent kinase inhibitor 1 Proteins 0.000 claims 1
- 102000011782 Keratins Human genes 0.000 claims 1
- 108010076876 Keratins Proteins 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N Navitoclax Chemical group C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 210000002374 Sebum Anatomy 0.000 claims 1
- 230000003712 anti-aging Effects 0.000 claims 1
- 230000000844 anti-bacterial Effects 0.000 claims 1
- 230000000843 anti-fungal Effects 0.000 claims 1
- 230000003110 anti-inflammatory Effects 0.000 claims 1
- 230000003078 antioxidant Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000002222 downregulating Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 230000001530 keratinolytic Effects 0.000 claims 1
- 230000003020 moisturizing Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Claims (17)
- 癌ではない炎症性疾患または線維性疾患の処置に用いられる、Bcl−xLおよび/またはBcl−wの活性および/または量を下方制御する薬剤。
- 前記薬剤が化学物質である、請求項1に記載の薬剤。
- 前記薬剤がBcl−xLおよび/またはBcl−wをターゲティングするポリヌクレオチド薬である、請求項1に記載の薬剤。
- (i)Bcl−xLおよび/またはBcl−wの活性および/または量を下方制御する薬剤;および
(ii)p21の活性および/または量を下方制御する薬剤
を含む、医薬品。 - 皮脂調節剤、抗菌薬および/または抗真菌薬、角質溶解薬および/または角質調節剤、収斂薬、抗炎症剤および/または抗刺激剤、抗酸化剤および/またはフリーラジカル消去剤、瘢痕形成剤、老化防止剤、および保湿剤からなる群から選択される少なくとも1つの薬剤をさらに含む、請求項4に記載の医薬品。
- 薬学的に許容され得るキャリアおよび活性薬剤としての以下:
(i)Bcl−xLおよび/またはBcl−wの活性および/または量を下方制御する薬剤;および
(ii)p21の活性および/または量を下方制御する薬剤
を含む薬学的組成物。 - 局所送達用に生成された、請求項6に記載の薬学的組成物。
- 炎症性疾患または線維性疾患の処置のために使用され、前記疾患が癌ではない、サイクリン依存性キナーゼインヒビター1(p21)の活性および/または量を下方制御する薬剤。
- 前記疾患が軟骨変性に関連する、請求項1〜3または8のいずれか一項に記載の薬剤。
- 前記疾患が、肝臓線維症、創傷治癒、皮膚線維症、肺疾患、腎臓線維症、前立腺炎、アテローム性動脈硬化症、関節炎、および膵炎からなる群から選択される、請求項1〜3または8のいずれか一項に記載の薬剤。
- キャリア、p21の活性および/または量を下方制御する少なくとも1つの活性薬剤、ならびにBcl−xLおよび/またはBcl−wの活性および/または量を下方制御する少なくとも1つの活性薬剤を含む組成物であって、局所投与のために処方される、組成物。
- 前記Bcl−xLおよび/またはBcl−wの活性および/または量を下方制御する少なくとも1つの活性薬剤がABT−737またはABT−263である、請求項11に記載の組成物。
- 前記肺疾患が慢性閉塞性肺疾患(COPD)を含む、請求項10に記載の薬剤。
- 局所投与用組成物として生成される、請求項1に記載の薬剤。
- 前悪性病変の処置に用いられる、Bcl−xLおよび/またはBcl−wの活性および/または量を下方制御する薬剤。
- (i)Bcl−xLおよび/またはBcl−wの活性および/または量を下方制御する薬剤;および
(ii)p21の活性および/または量を下方制御する薬剤
を含む、前悪性病変の処置に用いられる組成物。 - 前記前悪性病変が、膵臓の前悪性病変である、請求項15に記載の薬剤または請求項16に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361814286P | 2013-04-21 | 2013-04-21 | |
US61/814,286 | 2013-04-21 | ||
PCT/IL2014/050358 WO2014174511A1 (en) | 2013-04-21 | 2014-04-13 | Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016516808A JP2016516808A (ja) | 2016-06-09 |
JP2016516808A5 true JP2016516808A5 (ja) | 2017-05-25 |
Family
ID=50877543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016508288A Pending JP2016516808A (ja) | 2013-04-21 | 2014-04-13 | Bcl−xLおよび/またはBcl−wの活性および/または量を下方制御するための薬剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20160122758A1 (ja) |
EP (1) | EP2988767A1 (ja) |
JP (1) | JP2016516808A (ja) |
CN (1) | CN105377289A (ja) |
BR (1) | BR112015026702A2 (ja) |
CA (1) | CA2909380A1 (ja) |
MX (1) | MX2015014582A (ja) |
RU (1) | RU2015149680A (ja) |
WO (1) | WO2014174511A1 (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
CN104125836A (zh) | 2011-12-13 | 2014-10-29 | 巴克老龄化研究所 | 改善医疗治疗的方法 |
WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
US10279018B2 (en) | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
IL311537A (en) | 2014-01-28 | 2024-05-01 | Mayo Found Medical Education & Res | Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
WO2015171591A1 (en) | 2014-05-05 | 2015-11-12 | Board Of Trustees Of The University Of Arkansas | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
CA2955972A1 (en) | 2014-07-22 | 2016-01-28 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
JP2018508569A (ja) * | 2015-02-06 | 2018-03-29 | ユニティ バイオテクノロジー インコーポレイテッド | 老化関連状態の治療における化合物および使用 |
US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
EP3261612A1 (en) * | 2015-02-26 | 2018-01-03 | Yeda Research and Development Co. Ltd | Method of promoting hair growth |
EP3297680A2 (en) | 2015-05-20 | 2018-03-28 | Yeda Research and Development Co. Ltd | Method of targeting senescent cells |
WO2017002120A1 (en) * | 2015-07-02 | 2017-01-05 | Yeda Research And Development Co. Ltd. | Selective inhibitors of senescent cells and uses thereof |
US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
CN110312508A (zh) * | 2017-02-22 | 2019-10-08 | 国立癌研究院 | 含有棉酚和苯乙双胍作为活性成分的预防和治疗胰腺癌的药物组合物 |
US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
US10689416B2 (en) | 2017-12-30 | 2020-06-23 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
JP7080346B2 (ja) | 2018-04-30 | 2022-06-03 | ユニティ バイオテクノロジー インコーポレイテッド | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるホスホノアミダート |
CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
CN109387493B (zh) * | 2018-09-21 | 2020-12-22 | 山东大学 | 一种pH响应型自辅因子DNAzyme ZnO纳米探针及其制备方法与应用 |
US20220016156A1 (en) * | 2018-12-05 | 2022-01-20 | Nitto Denko Corporation | Rnai molecule for treating cancer |
CN111973578A (zh) * | 2020-08-03 | 2020-11-24 | 天津医科大学 | C188-9、Venetoclax、Bumetanide在纤维化疾病药物中的应用 |
CN112294962B (zh) * | 2020-11-13 | 2023-06-06 | 上海长海医院 | Bcl-2及bcl-xl抑制剂在瘢痕治疗中的应用 |
WO2022144882A2 (en) | 2020-12-28 | 2022-07-07 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
KR20230133859A (ko) | 2020-12-28 | 2023-09-19 | 1이 테라퓨틱스 엘티디. | p21 mRNA 표적화 DNA자임 |
CN113633642A (zh) * | 2021-08-26 | 2021-11-12 | 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) | Abt-263在制备抑制角膜移植免疫排斥反应的药物中的应用 |
WO2023064937A1 (en) * | 2021-10-14 | 2023-04-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Programmable delivery platforms for rna structures |
WO2023096448A1 (ko) * | 2021-11-29 | 2023-06-01 | 에스케이케미칼 주식회사 | 오바토클락스 대사성 질환 및 섬유화 질환 치료 용도 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
CA2006008C (en) | 1988-12-20 | 2000-02-15 | Donald J. Kessler | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
US6933286B2 (en) | 1991-03-19 | 2005-08-23 | R. Martin Emanuele | Therapeutic delivery compositions and methods of use thereof |
US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US5721138A (en) | 1992-12-15 | 1998-02-24 | Sandford University | Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use |
US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
AU755564B2 (en) | 1998-06-20 | 2002-12-12 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
CN1608131A (zh) * | 2001-10-26 | 2005-04-20 | 里伯药品公司 | 治疗胰腺癌的药物 |
WO2007130604A2 (en) | 2006-05-04 | 2007-11-15 | Baylor Research Institute | Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna |
CN101541379A (zh) * | 2006-08-11 | 2009-09-23 | 沃尔特及伊莱萨霍尔医学研究院 | 用于调控细胞存活的方法 |
WO2008017121A1 (en) * | 2006-08-11 | 2008-02-14 | The Walter And Eliza Hall Institute Of Medical Research | Methods for modulating apoptosis in platelets |
SI2194783T1 (sl) * | 2007-08-10 | 2017-12-29 | Vm Discovery, Inc. | Sestavki in metode za modulatorje apoptose |
US20110301192A1 (en) | 2008-10-01 | 2011-12-08 | The Regents Of The University Of California | Inhibitors of Cyclin Kinase Inhibitor p21 |
US20110020221A1 (en) * | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
JP2013505249A (ja) * | 2009-09-20 | 2013-02-14 | アボット・ラボラトリーズ | Bcl−2タンパク質関連疾患の治療における使用のためのABT−263結晶形態および溶媒和物 |
JP5998152B2 (ja) | 2011-01-25 | 2016-09-28 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Bcl−2/bcl−xl阻害剤およびそれを使用する治療方法 |
KR20140040715A (ko) * | 2011-04-08 | 2014-04-03 | 아프락시스 홀딩즈 인코포레이티드 | 신경계 장애 및 암의 치료를 위한 8-에틸-6-(아릴)피리도[2,3-d]피리미딘-7(8h)-온 |
WO2012168401A1 (en) * | 2011-06-09 | 2012-12-13 | Isdin, S.A. | Use of photolyase for reducing or improving subclinical field cancerization associated with actinic keratosis |
WO2013070807A1 (en) * | 2011-11-07 | 2013-05-16 | The Regents Of The University Of Califonia | Niche targeting of quiescent cancer stem cells |
WO2014047427A2 (en) * | 2012-09-21 | 2014-03-27 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors |
-
2014
- 2014-04-13 RU RU2015149680A patent/RU2015149680A/ru not_active Application Discontinuation
- 2014-04-13 EP EP14727628.1A patent/EP2988767A1/en not_active Withdrawn
- 2014-04-13 US US14/784,312 patent/US20160122758A1/en not_active Abandoned
- 2014-04-13 BR BR112015026702A patent/BR112015026702A2/pt not_active IP Right Cessation
- 2014-04-13 MX MX2015014582A patent/MX2015014582A/es unknown
- 2014-04-13 WO PCT/IL2014/050358 patent/WO2014174511A1/en active Application Filing
- 2014-04-13 CN CN201480035042.7A patent/CN105377289A/zh active Pending
- 2014-04-13 CA CA2909380A patent/CA2909380A1/en not_active Abandoned
- 2014-04-13 JP JP2016508288A patent/JP2016516808A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016516808A5 (ja) | ||
RU2015149680A (ru) | Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w | |
JP2014516942A5 (ja) | ||
JP2015078230A5 (ja) | ||
JP2017504611A5 (ja) | ||
RU2013121788A (ru) | Ингибиторы репликации вич | |
JP2014521735A5 (ja) | ||
JP2013509429A5 (ja) | ||
JP2014505733A5 (ja) | ||
JP2017537936A5 (ja) | ||
EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
JP2015098469A5 (ja) | ||
JP2020502132A5 (ja) | ||
JP2015516419A5 (ja) | ||
DOP2014000271A (es) | Nueva forma de dosificacion y formulacion de abediterol | |
JP2020529995A5 (ja) | ||
JP2014504636A5 (ja) | ||
JP2016515550A5 (ja) | ||
JP2014148552A5 (ja) | ||
JP2016540000A5 (ja) | ||
JP2014520874A5 (ja) | ||
MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
JP2011500731A5 (ja) | ||
MX2018014752A (es) | Beta-horquilla peptidomimetica con actividad inhibidora de elastasa y formas de dosificacion en aerosol de la misma. | |
JP2013518061A5 (ja) |